Skip to main content
Mabion S.A. logo

Mabion S.A. — Investor Relations & Filings

Ticker · MAB ISIN · PLMBION00016 LEI · 259400KG5JVQPPZL6X53 WAR Manufacturing
Open in API
Filings indexed 1,002 across all filing types
Latest filing 2020-11-05 Declaration of Voting R…
Country PL Poland
Listing WAR MAB

About Mabion S.A.

https://www.mabion.eu/en/

Mabion S.A. is an integrated Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services for the development and manufacturing of protein-based biotherapeutics. The company specializes in monoclonal antibodies and biosimilars, offering a complete workflow from cell line development and banking to process optimization and large-scale GMP manufacturing. Core competencies include upstream processing using mammalian cell cultures, downstream purification involving chromatography and viral clearance, and technology transfer for scale-up. Mabion partners with pharmaceutical and biotechnology companies to support both clinical and commercial supply, streamlining the path from gene to final drug product.

Recent filings

Filing Released Lang Actions
Trzecie wezwanie akcjonariuszy Mabion S.A. do złożenia dokumentów akcji w Spółce - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a formal notice from the Management Board of Mabion S.A. (Emitent) addressed to shareholders regarding the mandatory dematerialization of share certificates, citing specific Polish legislation (art. 16 of the Act of August 30, 2019). It details where and when to submit the documents. This action relates to the company's capital structure and the formal process of converting physical shares to electronic form, which is a significant corporate action affecting share ownership. This fits best under 'Capital/Financing Update' (CAP) as it directly concerns the structure and form of the company's capital instruments, or potentially 'Regulatory Filings' (RNS) if it were a generic announcement. However, given the specific nature of mandatory dematerialization and its impact on capital structure, CAP is a stronger fit than the general RNS fallback. It is not an earnings release, dividend notice, or management change. Since it is a direct instruction regarding the form of shares, CAP is the most appropriate specific category.
2020-11-05 Polish
Aktualizacja informacji dotyczących współpracy Spółki z Vaxine Pty Ltd. w zakresie potencjalnej szczepionki na Covid-19 - Content (EN)
Regulatory Filings Classification · 95% confidence The document is a short announcement (1213 characters) regarding an update on a cooperation agreement (MoU extension and new agreement for material release) related to a potential Covid-19 vaccine. It explicitly cites 'MAR art. 17 section 1 - confidential information,' which points towards a mandatory regulatory disclosure, likely related to market abuse regulation (MAR). Since the content is a specific, material update that doesn't fit the definitions for ER, IR, 10-K, or specific corporate actions (like DIV, SHA, DIRS), and it is an announcement of an event rather than a full report, the most appropriate general regulatory filing category is 'Regulatory Filings' (RNS). It is not a proxy statement (PSI), director dealing (DIRS), or earnings release (ER).
2020-10-29 English
Aktualizacja informacji dotyczących współpracy Spółki z Vaxine Pty Ltd. w zakresie potencjalnej szczepionki na Covid-19 - Content (PL)
Regulatory Filings Classification · 100% confidence The document text is very short (944 characters) and references a previous current report (raport bieżący nr 34/2020) to announce an update regarding an agreement (MoU) with Vaxine concerning the Covax-19 vaccine. It details the execution of a new agreement for material transfer and the extension of the MoU deadline. This type of specific, material, non-periodic update, especially when referencing prior regulatory filings, typically falls under general regulatory announcements in the Polish context, which corresponds best to the 'Regulatory Filings' (RNS) category as a miscellaneous, material disclosure that isn't a standard financial report (10-K, IR, ER) or a specific corporate action like dividend or management change. It is not a presentation (IP), a transcript (CT), or a formal audit report (AR). Given the nature of the update on an ongoing collaboration, RNS is the most appropriate fallback.
2020-10-29 Polish
Zawarcie umowy z Parexel na przeprowadzenie ostatniego badania klinicznego przed złożeniem wniosku w Europejskiej Agencji Leków (EMA) o dopuszczenie do obrotu produktu MabionCD20 - Content (EN)
Regulatory Filings Classification · 95% confidence The document is a formal announcement titled 'Subject matter: Conclusion of an agreement...' and explicitly states the 'Legal basis: Article 17(1) of MAR - confidential information.' This structure is characteristic of a regulatory disclosure concerning material, non-public information, often released via an official channel like a stock exchange wire service. The content details a significant operational event (entering an agreement for a clinical trial) rather than presenting periodic financial results (ER, IR, 10-K) or management changes (MANG). Since it is a specific, material announcement that doesn't fit the definitions for DIRS, DIV, CAP, or LTR, and it is not a presentation (IP) or a transcript (CT), the most appropriate general category for a mandatory, material regulatory disclosure that doesn't fit elsewhere is Regulatory Filings (RNS). The document length is short (3495 chars), but it is the primary disclosure itself, not an announcement *about* a report, so RPA is less fitting than RNS for this type of MAR disclosure.
2020-10-29 English
Zawarcie umowy z Parexel na przeprowadzenie ostatniego badania klinicznego przed złożeniem wniosku w Europejskiej Agencji Leków (EMA) o dopuszczenie do obrotu produktu MabionCD20 - Content (PL)
Regulatory Filings Classification · 90% confidence The document text is a formal announcement by the management of Mabion S.A. (Spółka) detailing the signing of an agreement with Parexel International (IRL) Limited to conduct a clinical trial (MabionCD20) for rheumatoid arthritis patients. It discusses the scope of work, the purpose (obtaining data for a Marketing Authorisation Application (MAA) to the EMA), estimated costs (€5.4 million), and timelines (completion planned for mid-2022). This content relates to significant operational and regulatory steps concerning product development and regulatory submissions, which falls under the scope of general corporate activity reporting. Since it is not a standard financial report (10-K, IR, ER), a management discussion (MDA), or a specific legal/financing event, it is best classified as a general Regulatory Filing (RNS) or potentially a Legal Proceedings Report (LTR) if the focus was on litigation, but here it is about a contract for a clinical trial. Given the nature of reporting on contracts related to regulatory pathways, RNS is the most appropriate general regulatory fallback, although it strongly relates to product development. However, none of the specific codes (like LTR for lawsuits) fit perfectly. Since it is a formal report about a significant business contract impacting regulatory strategy, RNS (Regulatory Filings / miscellaneous announcement) is the best fit among the provided options, as it is a 'raport bieżący' (current report) about a material event.
2020-10-29 Polish
Podpisanie wstępnego porozumienia dotyczącego współpracy w zakresie badań, rozwoju i komercjalizacji przeciwciał leku MabionCD20 w określonych wskazaniach klinicznych w obszarze chorób rzadkich. - ...
Regulatory Filings Classification · 96% confidence The document is a formal announcement regarding the signing of a Memorandum of Understanding (MoU) between Mabion S.A. and Taxon Therapeutics Ltd concerning the research, development, and commercialization of an antibody (MabionCD20). This type of announcement, which details a significant business agreement, partnership, or potential transaction (like a collaboration leading to commercialization), fits best under the category of M&A Activity (TAR) or potentially Regulatory Filings (RNS) if it were a general disclosure. However, since it explicitly details a strategic agreement involving future commercial rights and development, it strongly aligns with the scope of 'M&A Activity' (TAR), which often encompasses significant strategic alliances and potential takeovers/mergers, even if this is just an initial understanding. Given the options, TAR is the most specific fit for a major strategic business deal announcement. It is not an earnings release (ER), a capital change (CAP), or a director's dealing (DIRS). It is a specific business transaction announcement.
2020-10-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.